Bioinvenu is a company that specializes in developing and providing cell-based protein-protein interaction assay technologies, specifically the LinkLight assay platform. The company's core business involves designing and manufacturing assay-ready cells and monoclonal cell lines for various signaling pathways, including G-protein coupled receptors (GPCRs), nuclear hormone receptors (NHRs), receptor tyrosine kinases (RTKs), and kinase signaling pathways. Bioinvenu's products and services include custom protein-protein LinkLight development, custom cell-line generation, and compound profiling. The company's technology is designed to detect molecules that modulate protein-protein interactions in live cells, providing a tool for researchers to study cellular signaling pathways and develop new therapies. However, it appears that Reaction Biology Corporation has acquired the LinkLight cell-based protein-protein interaction assay platform and all associated services, cell lines, and products from Bioinvenu.

BioInvenu Corporation is a biotech company. Our mission is to provide the proprietary cell-based assay products and services to drug discovery researchers. BioInvenu is dedicated to develop assay products and services by utilizing a novel cell-based protein-protein interaction assay technology, LinkLight™ technology.

GPCR beta-arrestin LinkLight assay cells, Receptor Tyrosine kinase LinkLight Assay cells, non-receptor kinase LinkLight assay cells, protein-protein interaction LinkLight assays

Compound profiling and library screening
PXR assay

2010